Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of “Buy” from Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has earned a consensus rating of “Buy” from the thirteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $180.09.

ALNY has been the topic of several analyst reports. Barclays boosted their price target on shares of Alnylam Pharmaceuticals from $196.00 to $216.00 and gave the stock an “overweight” rating in a report on Wednesday, August 4th. BMO Capital Markets boosted their price target on shares of Alnylam Pharmaceuticals from $174.00 to $196.00 and gave the stock a “market perform” rating in a report on Friday, August 27th. They noted that the move was a valuation call. Piper Sandler cut shares of Alnylam Pharmaceuticals from an “overweight” rating to a “neutral” rating and boosted their target price for the company from $45.00 to $47.00 in a research note on Wednesday, August 4th. UBS Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the company from $141.00 to $215.00 in a research note on Monday, October 4th. Finally, HC Wainwright boosted their target price on shares of Alnylam Pharmaceuticals from $235.00 to $250.00 and gave the company a “buy” rating in a research note on Friday, August 13th.

In related news, CEO John Maraganore sold 33,979 shares of the company’s stock in a transaction that occurred on Friday, August 13th. The shares were sold at an average price of $199.78, for a total transaction of $6,788,324.62. Following the sale, the chief executive officer now owns 248,744 shares of the company’s stock, valued at approximately $49,694,076.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Laurie Keating sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 5th. The stock was sold at an average price of $188.95, for a total transaction of $1,889,500.00. Following the sale, the executive vice president now directly owns 13,008 shares in the company, valued at approximately $2,457,861.60. The disclosure for this sale can be found here. Insiders have sold a total of 97,043 shares of company stock worth $19,237,561 in the last ninety days. 2.30% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of ALNY. Koshinski Asset Management Inc. bought a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth $44,000. Wolverine Asset Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 3,023.1% in the 1st quarter. Wolverine Asset Management LLC now owns 406 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 393 shares in the last quarter. IFP Advisors Inc boosted its stake in shares of Alnylam Pharmaceuticals by 914.3% in the 2nd quarter. IFP Advisors Inc now owns 355 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 320 shares in the last quarter. HM Payson & Co. boosted its stake in shares of Alnylam Pharmaceuticals by 121.4% in the 1st quarter. HM Payson & Co. now owns 465 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 255 shares in the last quarter. Finally, Capital Analysts LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $68,000. 93.34% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals stock traded down $4.87 during midday trading on Monday, hitting $203.69. 2,368 shares of the stock were exchanged, compared to its average volume of 625,743. Alnylam Pharmaceuticals has a 52-week low of $119.29 and a 52-week high of $212.00. The stock has a market capitalization of $24.21 billion, a price-to-earnings ratio of -26.82 and a beta of 1.22. The business’s 50-day moving average price is $195.73 and its 200-day moving average price is $169.76. The company has a quick ratio of 4.76, a current ratio of 4.91 and a debt-to-equity ratio of 0.51.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Monday, August 2nd. The biopharmaceutical company reported ($1.61) earnings per share for the quarter, hitting the consensus estimate of ($1.61). Alnylam Pharmaceuticals had a negative net margin of 128.96% and a negative return on equity of 88.43%. The business had revenue of $220.55 million for the quarter, compared to analysts’ expectations of $193.66 million. During the same period in the previous year, the company earned ($1.67) earnings per share. The firm’s revenue for the quarter was up 112.1% compared to the same quarter last year. On average, sell-side analysts predict that Alnylam Pharmaceuticals will post -6.15 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The firm’s products include ONPATTRO, GIVLAARI, and OXLUMO. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.

Further Reading: Trading Strategy

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.